OmniAb Inc (OABI)
OmniAb Inc. is a biotechnology company listed on NASDAQ under the ticker OABI. The company licenses discovery research technology to pharmaceutical and biotechnology companies as well as academic institutions to support therapeutic discovery in the United States, Europe, Japan, China, and Canada. Its platform is designed to generate and screen diverse antibody repertoires to help identify target-binding proteins for drug development programs. OmniAb also develops a range of proprietary and engineered animal-based technologies, including OmniRat, OmniChicken, and OmniMouse, along with bispecific discovery platforms such as OmniFlic and OmniClic, the cow-inspired OmniTaur system, the single-domain antibody platform OmnidAb, and the OmniDeep suite of in silico AI and machine learning tools. The company was founded in 2012 and is headquartered in Emeryville, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OABI
|
$2.93
|
-34.4% Downside
|
Overvalued
|
$8.40
|
87.9% Upside
|
Bargain
|
Good
|
0.0%
|
November 17, 2026
|
2.5x
|
16.9x
|
649.9 M
|
616.8 M
|
2.8%
|
81.3%
|
9.8
|
41.0%
|
